WO2012155134A3 - Assay reagents for a neurogranin diagnostic kit - Google Patents

Assay reagents for a neurogranin diagnostic kit Download PDF

Info

Publication number
WO2012155134A3
WO2012155134A3 PCT/US2012/037774 US2012037774W WO2012155134A3 WO 2012155134 A3 WO2012155134 A3 WO 2012155134A3 US 2012037774 W US2012037774 W US 2012037774W WO 2012155134 A3 WO2012155134 A3 WO 2012155134A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurogranin
assay reagents
present
diagnostic kit
provides
Prior art date
Application number
PCT/US2012/037774
Other languages
French (fr)
Other versions
WO2012155134A2 (en
Inventor
Allen Dale EVERETT
Jun Yang
Zongming Fu
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Priority to JP2014510535A priority Critical patent/JP2014518624A/en
Priority to EP12782967.9A priority patent/EP2707389B1/en
Priority to US14/117,111 priority patent/US20140141458A1/en
Publication of WO2012155134A2 publication Critical patent/WO2012155134A2/en
Publication of WO2012155134A3 publication Critical patent/WO2012155134A3/en
Priority to US15/280,780 priority patent/US9709578B2/en
Priority to US15/639,210 priority patent/US10215764B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.
PCT/US2012/037774 2011-05-12 2012-05-14 Assay reagents for a neurogranin diagnostic kit WO2012155134A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2014510535A JP2014518624A (en) 2011-05-12 2012-05-14 Assay reagent for neurogranin diagnostic kit
EP12782967.9A EP2707389B1 (en) 2011-05-12 2012-05-14 Assay reagents for a neurogranin diagnostic kit
US14/117,111 US20140141458A1 (en) 2011-05-12 2012-05-14 Assay reagents for a neurogranin diagnostic kit
US15/280,780 US9709578B2 (en) 2011-05-12 2016-09-29 Assay reagents for a neurogranin diagnostic kit
US15/639,210 US10215764B2 (en) 2011-05-12 2017-06-30 Assay reagents for a neurogranin diagnostic kit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485375P 2011-05-12 2011-05-12
US61/485,375 2011-05-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/117,111 A-371-Of-International US20140141458A1 (en) 2011-05-12 2012-05-14 Assay reagents for a neurogranin diagnostic kit
US15/280,780 Continuation US9709578B2 (en) 2011-05-12 2016-09-29 Assay reagents for a neurogranin diagnostic kit

Publications (2)

Publication Number Publication Date
WO2012155134A2 WO2012155134A2 (en) 2012-11-15
WO2012155134A3 true WO2012155134A3 (en) 2013-06-13

Family

ID=47140053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/037774 WO2012155134A2 (en) 2011-05-12 2012-05-14 Assay reagents for a neurogranin diagnostic kit

Country Status (4)

Country Link
US (3) US20140141458A1 (en)
EP (1) EP2707389B1 (en)
JP (1) JP2014518624A (en)
WO (1) WO2012155134A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
EP2707389B1 (en) 2011-05-12 2019-10-30 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
EP2825893A4 (en) 2012-03-13 2016-03-16 Univ Johns Hopkins Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
US20160130585A1 (en) 2013-05-28 2016-05-12 The Johns Hopkins University Aptamers for the treatment of sickle cell disease
US10534003B2 (en) 2013-07-17 2020-01-14 The Johns Hopkins University Multi-protein biomarker assay for brain injury detection and outcome
FR3025317B1 (en) * 2014-08-26 2022-09-23 Imabiotech METHOD FOR CHARACTERIZING A SAMPLE BY MASS SPECTROMETRY IMAGING
EP3242134A1 (en) 2016-05-04 2017-11-08 Euroimmun Medizinische Labordiagnostika AG Assay for the diagnosis of a neurological disease
EP3630804A4 (en) * 2017-05-23 2021-06-16 Brainbox Solutions, Inc. Biomarker levels and neuroimaging for detecting, monitoring and treating brain injury or trauma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143519A2 (en) * 2008-05-23 2009-11-26 The Johns Hopkins University Biomarkers for myocardial ischemia

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SE462454B (en) 1988-11-10 1990-06-25 Pharmacia Ab METHOD FOR USE IN BIOSENSORS
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (en) 1990-08-29 1998-02-19 Genpharm Int Production and Use Non-human transgene heterologous antibodies for production
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
ES2201077T3 (en) 1993-05-28 2004-03-16 Baylor College Of Medicine METHOD AND SPECTROMETER OF MASSES FOR DESORTION AND IONIZATION OF ANALYTS.
US5866434A (en) 1994-12-08 1999-02-02 Meso Scale Technology Graphitic nanotubes in luminescence assays
US6673533B1 (en) 1995-03-10 2004-01-06 Meso Scale Technologies, Llc. Multi-array multi-specific electrochemiluminescence testing
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
BR9607193B1 (en) 1995-03-10 2009-01-13 multispecific multispecific electrochemical test.
US6207369B1 (en) 1995-03-10 2001-03-27 Meso Scale Technologies, Llc Multi-array, multi-specific electrochemiluminescence testing
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6319670B1 (en) 1995-05-09 2001-11-20 Meso Scale Technology Llp Methods and apparatus for improved luminescence assays using microparticles
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6413783B1 (en) 1997-09-18 2002-07-02 Meso Scale Technologies, Llc Assay sonication apparatus and methodology
ATE340870T1 (en) 1998-04-03 2006-10-15 Compound Therapeutics Inc ADDRESSABLE PROTEIN ARRAYS
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6780606B1 (en) 1999-02-26 2004-08-24 Synx Pharma, Inc. Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
AU2001291217A1 (en) 2000-09-22 2002-04-02 University Of Aarhus Novel compositions and methods for lymphoma and leukemia
US7842246B2 (en) 2001-06-29 2010-11-30 Meso Scale Technologies, Llc Assay plates, reader systems and methods for luminescence test measurements
DE60236732D1 (en) 2001-07-30 2010-07-29 Meso Scale Technologies Llc ASSAY ELECTRODES WITH REAL-ESTABLISHED LIPID / PROTEIN LAYERS AND PROCESS FOR THEIR PREPARATION AND USE
JP2005522669A (en) 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド Diagnostic markers for stroke and brain injury and methods of use thereof
EP1436598B1 (en) 2001-09-10 2013-11-27 Meso Scale Technologies LLC Assay buffer, compositions containing the same, and methods of using the same
WO2003023360A2 (en) 2001-09-10 2003-03-20 Meso Scale Technologies, Llc Methods and apparatus for conducting multiple measurements on a sample
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
AU2002352355B2 (en) 2001-12-05 2008-04-03 Sengenics Corporation Pte Ltd Protein arrays for allelic variants and uses thereof
US20040014143A1 (en) * 2002-05-29 2004-01-22 Haskins William E. Method and apparatus for detecting and monitoring peptides, and peptides identified therewith
US7036946B1 (en) 2002-09-13 2006-05-02 Rockwell Collins, Inc. LCD backlight with UV light-emitting diodes and planar reactive element
CA3171720C (en) 2002-12-26 2024-01-09 Meso Scale Technologies, Llc. Methods for conducting electrochemiluminescence measurements
US7981362B2 (en) 2003-11-04 2011-07-19 Meso Scale Technologies, Llc Modular assay plates, reader systems and methods for test measurements
US7396654B2 (en) 2004-04-15 2008-07-08 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for traumatic brain injury
DE602005013957D1 (en) 2004-06-03 2009-05-28 Meso Scale Technologies Llc METHOD FOR PERFORMING FULL BLOOD TESTS
JP5190261B2 (en) * 2004-06-25 2013-04-24 ワシントン・ユニバーシティ Markers for brain injury
US20060257943A1 (en) 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
US7884260B2 (en) 2005-06-14 2011-02-08 University Of Chicago Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
US20080026485A1 (en) 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
US8088584B2 (en) 2006-10-16 2012-01-03 Bayer Schering Pharma Aktiengesellschaft LTBP2 as a biomarker and diagnostic target
EP2015196A1 (en) 2007-06-28 2009-01-14 Siemens Aktiengesellschaft Programmer interface for manufacturing execution system
US20110143375A1 (en) 2008-08-11 2011-06-16 Banyan Blomakers, Inc. Biomarker detection process and assay of neurological condition
GB201008541D0 (en) 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
EP2707389B1 (en) 2011-05-12 2019-10-30 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143519A2 (en) * 2008-05-23 2009-11-26 The Johns Hopkins University Biomarkers for myocardial ischemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI [online] 14 January 2011 (2011-01-14), XP003030202, Database accession no. NP_006167 *
PAK, J. ET AL.: "Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic platicity, and spatial learning: a study with knockout mice", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 21, 10 October 2000 (2000-10-10), pages 11232 - 11237, XP002250333 *
TOK, J. ET AL.: "Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin", CHEM. COMMUN., 18 March 2008 (2008-03-18), pages 1883 - 1885, XP055071723 *

Also Published As

Publication number Publication date
US20170315138A1 (en) 2017-11-02
JP2014518624A (en) 2014-08-07
US20140141458A1 (en) 2014-05-22
US9709578B2 (en) 2017-07-18
EP2707389A2 (en) 2014-03-19
WO2012155134A2 (en) 2012-11-15
US10215764B2 (en) 2019-02-26
EP2707389A4 (en) 2015-08-12
EP2707389B1 (en) 2019-10-30
US20170038397A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
WO2012155134A3 (en) Assay reagents for a neurogranin diagnostic kit
WO2010118411A3 (en) Improved methods for conducting assays
EP4219750A3 (en) Improved methods for conducting multiplexed assays
EP4249605A3 (en) Methods for analyte detection
GB201200658D0 (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
MX340453B (en) Biomarkers for lung cancer.
GB201118647D0 (en) Transgenic non-human assay vertebrates, assays and kits
GB201014805D0 (en) Microfluidics based assay device
PH12014502581A1 (en) Aptamer-based mulitiplexed assays
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
HUE036585T2 (en) Multigene prognostic assay for lung cancer
PT2507635E (en) Biochemical serum biomarker
WO2010096674A3 (en) A+ biomarker assays
MX353954B (en) Aptamers and diagnostic methods for detecting the egf receptor.
WO2012170206A3 (en) Color-producing diagnostic systems, reagents and methods
WO2013115410A3 (en) Anti-phospholipase d4 antibody
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
WO2013079981A3 (en) Biomarker-based methods and biochips for aiding the diagnosis of stroke
WO2014151290A3 (en) Assay for predictive biomarkers
MX2015004419A (en) Detecting an analyte and determining the concentration of an analyte using magnetizable beads.
WO2011133450A3 (en) Serology assays
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
GB201119585D0 (en) Assay
WO2013165969A3 (en) Methods and kits for diagnosing heparin-induced thrombocytopenia
MX2014001224A (en) Assay for detection of jc virus dna.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12782967

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014510535

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012782967

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 14117111

Country of ref document: US